IDEXX Laboratories, Inc. $IDXX is Quantum Capital Management LLC NJ’s 8th Largest Position

Quantum Capital Management LLC NJ lessened its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 25.5% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 77,825 shares of the company’s stock after selling 26,602 shares during the period. IDEXX Laboratories comprises about 5.5% of Quantum Capital Management LLC NJ’s investment portfolio, making the stock its 8th biggest holding. Quantum Capital Management LLC NJ’s holdings in IDEXX Laboratories were worth $49,722,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in IDXX. Parallel Advisors LLC raised its holdings in IDEXX Laboratories by 1.1% in the 3rd quarter. Parallel Advisors LLC now owns 2,597 shares of the company’s stock worth $1,659,000 after acquiring an additional 28 shares during the last quarter. Meiji Yasuda Life Insurance Co bought a new position in IDEXX Laboratories in the 3rd quarter valued at approximately $261,000. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund boosted its stake in IDEXX Laboratories by 127.8% during the 3rd quarter. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund now owns 4,100 shares of the company’s stock valued at $2,619,000 after purchasing an additional 2,300 shares during the last quarter. Grantham Mayo Van Otterloo & Co. LLC purchased a new stake in IDEXX Laboratories during the 3rd quarter valued at $949,000. Finally, Munich Reinsurance Co Stock Corp in Munich bought a new stake in shares of IDEXX Laboratories in the 3rd quarter worth $4,991,000. Institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Wall Street Zen cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Piper Sandler dropped their price objective on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research report on Monday, February 9th. Weiss Ratings downgraded IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. BTIG Research decreased their target price on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Finally, Barclays lowered their target price on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Seven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $783.33.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX opened at $608.41 on Friday. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $769.98. The firm has a market capitalization of $48.44 billion, a price-to-earnings ratio of 46.55, a price-to-earnings-growth ratio of 3.70 and a beta of 1.66. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. The firm has a 50 day moving average of $666.94 and a 200 day moving average of $668.42.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing the consensus estimate of $2.93 by ($0.01). The business had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The firm’s revenue was up 14.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Insider Transactions at IDEXX Laboratories

In related news, CEO Jonathan Jay Mazelsky sold 23,326 shares of the firm’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $657.55, for a total value of $15,338,011.30. Following the transaction, the chief executive officer directly owned 83,606 shares of the company’s stock, valued at approximately $54,975,125.30. This trade represents a 21.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Nimrata Hunt sold 1,758 shares of IDEXX Laboratories stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total value of $1,115,574.06. Following the transaction, the executive vice president owned 18,141 shares in the company, valued at $11,511,734.37. This trade represents a 8.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 45,957 shares of company stock worth $29,862,109 over the last three months. 0.98% of the stock is currently owned by insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.